Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma

Journal of Korean Medical Science

Volumn 27, Issue 9, 2012, Pages 1019-1026

  Lee, Jandee ^a   Nah, Kuk Young ^b   Kim, Ra Mi ^b   Oh, Yeon Ju ^b   An, Young Sil ^b   Yoon, Joon Kee ^b   An, Gwang Il ^c   Choi, Tae Hyun ^c   Cheon, Gi Jeong ^c,d   Soh, Euy Young ^b   Chung, Woong Youn ^e  

^a Eulji University School of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Korea Institute of Radiation and Medical Science   (South Korea)

^d Korea University Ansan Hospital   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

124I PET; 18F FDG PET; Differentiated Thyroid Carcinoma; Elevated Thyroglobulin Levels; Negative 131I Whole Body Scan; PET CT; Recurrence

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; THYROGLOBULIN;

ADULT; AGED; ARTICLE; BLOOD; CARCINOMA; CASE REPORT; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; NECK; PROSPECTIVE STUDY; RECURRENT DISEASE; SCINTISCANNING; THYROID TUMOR; THYROIDECTOMY; WHOLE BODY IMAGING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NECK; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECURRENCE; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; WHOLE BODY IMAGING;

EID: 84866407060     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.9.1019     Document Type: Article

References (31)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
2. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-8.
3. Lin JD, Huang MJ, Juang JH, Chao TC, Huang BY, Chen KW, Chen JY, Li KL, Chen JF, Ho YS. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 1999; 9: 1227-35.
4. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998; 83: 4195-203.
5. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999; 22: 3-7.
6. Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin North Am 1996; 25: 93-113.
7. Lubin E, Mechlis-Frisch S, Zatz S, Shimoni A, Segal K, Avraham A, Levy R, Feinmesser R. Serum thyroglobulin and iodine-131 whole-body scan in diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994; 35: 257-62.
8. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985; 60: 376-80.
9. Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001; 42: 71-6.
10. Krishnamurthy S, Bedi DG, Caraway NP. Ultrasound-guided fine-needle aspiration biopsy of the thyroid bed. Cancer 2001; 93: 199-205.
11. Frilling A, Görges R, Tecklenborg K. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000; 128: 1067-74.
12. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A. Recombinant human thyrotropinstimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 3668-73.
13. Lubberink M, Abdul Fatah S, Brans B, Hoekstra OS, Teule GJ. The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma. Q J Nucl Med Mol Imaging 2008; 52: 30-6.
14. Freudenberg LS, Frilling A, Kühl H, Müller SP, Jentzen W, Bockisch A, Antoch G. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 2007; 17: 3139-47.
15. Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 2007; 32: 690-5.
16. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006; 47: 616-24.
17. Zuijdwijk MD, Vogel WV, Corstens FH, Oyen WJ. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Nucl Med Commun 2008; 29: 636-41.
18. Bertagna F, Bosio G, Biasiotto G, Rodella C, Puta E, Gabanelli S, Lucchini S, Merli G, Savelli G, Giubbini R, et al. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med 2009; 34: 756-61.
19. Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, Bockisch A, Görges R. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging 2008; 35: 950-7.
20. Freudenberg L, Jentzen W, Müller SP, Bockisch A. Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging 2008; 35: 502-8.
21. Phan HT, Jager PL, Paans AM, Plukker JT, Sturkenboom MG, Sluiter WJ, Wolffenbuttel BH, Dierckx RA, Links TP. The diagnostic value of 124IPET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35: 958-65.
22. Capoccetti F, Criscuoli B, Rossi G, Ferretti F, Manni C, Brianzoni E. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2009; 53: 536-45.
23. Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2008; 49: 1017-23.
24. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
25. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004; 89: 91-5.
26. Filetti S, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinology 1987; 120: 2576-81.
27. Ruiz Franco-Baux JV, Borrego Dorado I, Gómez Camarero P, Rodríguez Rodríguez JR, Vázquez Albertino RJ, Navarro González E, Astorga Jiménez R. F-18-Fluorodeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan. Rev Esp Med Nucl 2005; 24: 5-13.
28. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84: 2291-302.
29. Pentlow KS, Graham MC, Lambrecht RM, Daghighian F, Bacharach SL, Bendriem B, Finn RD, Jordan K, Kalaigian H, Karp JS, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med 1996; 37: 1557-62.
30. Lambrecht RM, Woodhouse N, Phillips R, Wolczak D, Qureshi A, Reyes ED, Graser C, Al-Yanbawi S, Al-Rabiah A, Meyer W. Investigational study of iodine-124 with a positron camera. Am J Physiol Imaging 1988; 3: 197-200.
31. van Tol KM, Jager PL, de Vries EG, Piers DA, Boezen HM, Sluiter WJ, Dullaart RP, Links TP. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003; 148: 589-96.